中国生物技术股份有限公司 specializes in the research and development of vaccines and new drugs, contributing to public health.

中国生物技术股份有限公司

Nanjing Vazyme Biotech Co., Ltd., a biotechnology company, engages in the research, development, and production of enzymes, antigens, antibodies, and polymer organic materials. The company offers scientific research reagents, such as PCR clone point mutation, nucleic acid extraction, reverse transcription, qPCR, cell/protein, gene editing series, and instant granules; high-throughput sequencing library construction reagents, including DNA and RNA library, single cell epigenetic, magnetic, quantitative series, and cell-free DNA storage and extractions; and biomedical reagents and services. It serves scientific research institutions, high-throughput sequencing service companies, molecular diagnostic reagent manufacturers, pharmaceutical companies, CRO companies, hospitals, and other medical institutions. The company was founded in 2012 and is based in Nanjing, China.

Nanjing Vazyme Biotech Co., Ltd.

China National Biotec Group Company Limited | 801 followers on LinkedIn. China National Biotec Group (CNBG), is a subsidiary of China National Pharmaceutical Group corporation (SINOPHARM), and has 6 subordinate biological products research institutes in Beijing, Changchun, Chengdu, Lanzhou, Shanghai and Wuhan as well as Beijing Tiantan Biological Products Co., Ltd. 

CNBG is a professional institute which has the longest history in vaccine and blood production research and development in China, and is the biggest biotech corporation combines research, development, production and supply in one. To date, the total assets of the group is 15.6 billion RMB, main operating revenue exceeds 5 billion RMB, is the fourth biggest vaccine manufacturer in the world.

Sr. Manager - BD, Licensing & Investment - Intl. Cooperation Dept - China National Biotec Group

Hai (Harrison) L.

Metric
Company Name	中国生物技术股份有限公司	Nanjing Vazyme Biotech Co., Ltd.
Symbol		688.11K
MSH ID	CN:COM:CNBG	COM:VAZYME
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	CN	CN
Stage		Series C
Employee Count		2.70K
Website	cnbg.com.cn	vazyme.com
LinkedIn	china-national-biotec-group-company-limited	vazyme
Founders

Metric
Market Cap		1.10B
Enterprise Value
Monthly Web Traffic		1.61K
Web Traffic Growth		-0.40
Valuation
Raised Capital		84.21M

Metric
Revenue		177.00M
Revenue (LTM)
Revenue (NTM)
Gross Profit		177.00M
EBITDA		-7.52M
Operating Income		-13.74M
Net Income		-9.72M
EPS		-0.02
Diluted EPS		-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.80
Operating Profit Margin		-0.05
EBITDA Margin		-0.04
Net Profit Margin		0.02
Return on Equity		0.01
Return on Assets		0.01
Return on Capital Employed		-0.02

COM

CN:COM:CNBG

中国生物技术股份有限公司

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-31.42
P/B Ratio		1.82
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		8.68
EV Multiple		393.78

Metric
Days Sales Outstanding		58.74
Days Payables Outstanding		80.75
Days Inventory Outstanding		600.52
Operating Cycle		697.89
Cash Conversion Cycle		462.35
Asset Turnover		0.27

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt		0.19
Operating Cash Flow/Sales		0.16
Free Cash Flow Yield		-0.07

Metric
Cash & Equivalents		270.54M
Accounts Receivable
Inventory		47.63M
Goodwill		17.95M
Debt to Capitalization		0.25
Debt to Assets		0.23
Current Ratio		2.76
Quick Ratio		4.09

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.17
SG&A to Revenue		0.05